Fighting the FDA’s Final Rule on LDTs
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
CEO Laurie Menser discusses the Association for Molecular Pathology’s court case against the FDA’s rule on laboratory-developed tests.
From - Laboratory Industry Report
In a month with an unusually heavy volume of diagnostic deal making, the headline story was Abbott Laboratories' $25 billion purchase of…
From - Diagnostic Testing & Emerging Technologies
Advanced diagnostic tests are emerging faster than the clinicians can document their clinical utility. All of this creates an interesting dilemma for…
From - Laboratory Industry Report
The Centers for Medicare and Medicaid Services (CMS) issued the final 2017 Clinical Laboratory Fee Schedule (CLFS) on Nov. 21. Here is a look at…
From - Laboratory Industry Report
Less than a month after its acquisition of neonatal specialty lab Sequenom, LabCorp acquired obstetric and gynecology testing firm…